Replies to post #364203 on Amarin Corp Plc (AMRN)

[lettruthringout]

I think Edding will want to try ...

... selling Vascepa on their own in China

Pfizer may wish to add Vascepa to its list of drugs that it markets in China ..and they can well afford to be an early minority investor in Eddingpharm prior in an IPO.

It looks like Edding has accrued substantial debt (current investors including Sequoia Capital, Orbimed Capital, Domain, Double Prestige, Forebright, Shanghai Pudong Development Bank, Credit Suisse, China Huarong Asset Management's Ace City, Abax Global Capital, etc.) and so Pfizer might want to wait awhile before making an investment behind a list of others.

Of course another wild card in all this is future relations between China and the West. That could tend to make some potential investors nervous. I set up an account six months ago so I could trade on the HKEX. Trump/Biden have prohibited U.S. persons from transacting in the publicly traded securities of Chinese companies that the Department of Defense has identified as CCMCs (Communist Chinese Military Companies), so you never know how far this will go. And, Hong Kong becomes more tightly in the grip of China with each passing day, and that also makes me less eager to invest in a company on the HKEX.

[couldbebetter]

Zip, If Pfizer truly has a good working relationship with Eddingpharm,
imagine what they could do if PFE acquired AMRN and worked with Edding
to optimize uptake of Vascepa (and Lipitor) in China. That relationship
between Edding and Pfizer should make a BO of AMRN by PFE more likely.
Of course, the sooner PFE gets a BO of AMRN to happen, the longer the
time frame they will have to reap revenues.